Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583382 | 0.94 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL4330810 | 0.90 | PDE4B (0.57) | PDE4BADORA1PDE5A | |
| SCHEMBL4340394 | 0.88 | PDE4B (0.75) | PDE4BADORA1PDE5A | |
| SCHEMBL583383 | 0.88 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL583313 | 0.87 | PDE4B (0.70) | PDE4BADORA1 | |
| SCHEMBL4338010 | 0.86 | PDE4B (0.74) | PDE4B | |
| SCHEMBL583135 | 0.85 | PDE4B (0.77) | PDE4B | |
| SCHEMBL583156 | 0.84 | PDE4B (0.77) | PDE4B | |
| SCHEMBL4330916 | 0.84 | PDE4B (0.74) | PDE4B | |
| SCHEMBL583438 | 0.83 | PDE4B (0.65) | PDE4BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885ADORA1 303/4885PDE5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.